following a full submission
erlotinib (Tarceva®) is accepted for use within NHS Scotland.
Indication under review: first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
In patients with advanced or metastatic NSCLC with EGFR mutations, erlotinib was associated with significantly improved progression-free survival compared with platinum-based doublet chemotherapy regimens. There are no mature overall survival data.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of erlotinib. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland.
Download detailed advice154KB (PDF)
Medicine details
- Medicine name:
- erlotinib (Tarceva)
- SMC ID:
- 749/11
- Indication:
- first line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 16 January 2012